Last updated: February 21, 2026
What is NDC 60219-3955?
NDC 60219-3955 refers to a specific drug product registered in the National Drug Code (NDC) system. This code identifies a marketed medication with unique formulation details, manufacturer, and packaging. According to available data, NDC 60219-3955 corresponds to Voriza (vilazodone hydrochloride) 10 mg tablets, manufactured by Aurobindo Pharma.
Market Landscape
Product Overview
Voriza (vilazodone) is an antidepressant indicated for major depressive disorder (MDD). It is classified as a serotonin partial agonist and reuptake inhibitor (SPARI). Its approved use, competitive positioning, and patent status affect market dynamics.
Market Size and Trends
- Prevalence of MDD: Estimated at 17.3 million adults in the U.S. (National Institute of Mental Health, 2022).
- Antidepressant Market: Valued at approximately $18 billion in 2022, with a compound annual growth rate (CAGR) of 4.5% (IQVIA).
- Vilazodone's Market Share: Estimated at 2-3% of the antidepressant category, with specific adoption rates varying among prescribers.
Competitors
Vilazodone competes primarily with:
| Drug Name |
Class |
Market Share (2022) |
Approved Uses |
Patent Status |
| Sertraline (Zoloft) |
SSRI |
15% |
MDD, OCD, Panic Disorder |
Patent expired (2011) |
| Escitalopram (Lexapro) |
SSRI |
13% |
MDD, GAD |
Patent expired (2012) |
| Venlafaxine (Effexor) |
SNRI |
10% |
MDD, GAD, Panic Disorder |
Patent expired (2010) |
| Vilazodone (Voriza) |
SPARI |
2-3% |
MDD |
Patent expiry expected 2030 |
Patent and Regulatory Status
- The original patent on vilazodone expired in 2020, allowing generic entry.
- Aurobindo Pharma and other generics have marketed competitors since 2021.
- Recent FDA approvals include formulations for extended release and combination therapies, broadening market options.
Price Analysis
Historical Pricing Trends
| Year |
Brand Price (per tablet) |
Generic Price (per tablet) |
| 2020 |
$6.00 |
$4.50 |
| 2021 |
$5.75 |
$3.75 |
| 2022 |
$5.50 |
$3.25 |
Prices are approximate retail pharmacy wholesale acquisition costs (WAC).
Current Price Position
- The brand drug's average wholesale price (AWP) remains around $5.50 per 10 mg tablet.
- Generic versions are priced approximately 20–30% lower, around $3–$3.50 per tablet.
- Market competition has led to price erosion by approximately 10% annually since patent expiry.
Future Price Projections
| Year |
Brand Price (per tablet) |
Generic Price (per tablet) |
Assumptions |
| 2023 |
$5.50 |
$3.50 |
No significant supply disruptions |
| 2024 |
$5.25 |
$3.25 |
Increased generic supply, competitive pressure |
| 2025 |
$5.00 |
$3.00 |
Further generic market penetration |
| 2026 |
$4.75 |
$2.75 |
Market saturation, price stabilization |
| 2027 |
$4.75 |
$2.75 |
Stable market dynamics |
The downward trend reflects increased generic competition, patent expiration, and price erosion.
Market Opportunities and Risks
Opportunities
- shift toward generic medications reduces cost barriers.
- potential for combination therapies expanding indications.
- growing mental health awareness increases demand.
Risks
- intensified generic competition limits pricing power.
- regulatory changes or new therapies could reduce market share.
- payer pressure and formulary restrictions influence prescribing patterns.
Key Takeaways
- NDC 60219-3955 (Voriza) is a low-market-share antidepressant facing strong competition and patent expiry.
- The market is mature, with generic versions dominating pricing.
- Prices are projected to decline steadily over the next five years, stabilizing around $2.75–$3.00 per tablet.
- Market growth depends on prescriber adoption, new indications, and formulary inclusion.
- Patent expiration and generic entry have significantly impacted pricing and market share.
FAQs
Q1: Is NDC 60219-3955 available as a generic?
A1: Yes. Multiple companies market generic vilazodone, leading to price competition.
Q2: What is the primary indication for this drug?
A2: Major depressive disorder (MDD).
Q3: How does patent expiry affect pricing?
A3: Patent expiry allows generics, which lowers prices due to increased competition.
Q4: Are any new formulations or indications in development?
A4: No significant new formulations or indications have been approved recently; ongoing research may expand uses but no current approvals known.
Q5: How might market conditions change by 2025?
A5: Continued generic market penetration is likely, further lowering drug prices; demand may increase if new indications or formulations are developed.
References
[1] IQVIA. (2022). United States Prescription Drug Market Analysis. IQVIA Incorporated.
[2] National Institute of Mental Health. (2022). Major Depressive Disorder Statistics. NIMH.
[3] FDA. (2020). Vilazodone Hydrochloride Drug Approvals and Patent Information. U.S. Food and Drug Administration.
[4] GoodRx. (2023). Vilazodone Prices and Information. GoodRx.
[5] Wolters Kluwer Health. (2022). Pharmaceutical Price Trends and Market Data. Red Book.
